An introduction to sample size calculations in clinical trials

Epidemiologia e Psichiatria Sociale

Volumn 16, Issue 4, 2007, Pages 299-301

  Accordini, Simone ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b Dipartimento di Medicina e Sanita' Pubblica   (Italy)

Author keywords

CHAT study; Clinical trials; Power analysis; Sample size

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPOTHESIS; METHODOLOGY; POWER ANALYSIS; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SCHIZOPHRENIA; SHORT SURVEY; STATISTICS;

EID: 38849162125     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1121189x00002475     Document Type: Short Survey

References (14)

1. Altman D.G. (1980). Statistics and ethics in medical research. III How large a sample? British Medical Journal 281, 1336-1338.
2. Barbui C., Cipriani A., Malvini L., Nosè M., Accordini S., Pontarollo F., Veronese A. & Tansella M. (2006). Trasformare la pratica clinica in ricerca. Un invito a partecipare allo studio CHAT. Rivista di Psichiatria 41, 326-330.
3. Barbui C., Veronese A. & Cipriani A. (2007). Explanatory and pragmatic trials. Epidemiologia e Psichiatria Sociale 16, 124-125.
4. Cipriani A., Nose M. & Barbui C. (2007). What is a risk ratio? Epidemiologia e Psichiatria Sociale 16, 20-21.
5. Chow S.C., Shao J. & Wang H. (2003). Sample Size Calculations in Clinical Research. Marcel Dekker: New York.
6. Christensen E. (2007). Methodology of superiority vs. equivalence trials and non-inferiority trials. Journal of Hepatology 46, 947-954.
7. Hintze J. (2004). NCSS and PASS. Kaysville: Number Cruncher Statistical Systems.
8. Hwang I.K. & Morikawa T. (1999). Design issues in noninferiority / equivalence trials. Drug Information Journal 33, 1205-1218.
9. ICH. E3 (1996). Structure and content of clinical study reports. July 1996. Retrieved July 26, 2007 from http://www.fda.gov/cder/guidance/iche3.pdf.
10. ICH. E9 (1998). Statistical principles for clinical trials. September 1998. Retrieved July 26, 2007 from http://www.fda.gov/cder/guidance/ICH_E9-fnl. pdf
11. ICH. E10 (2001). Choice of control group and related issues in clinical trials. May 2001. Retrieved July 26, 2007 from http://www.fda.gov/cder/guidance/ 4155fnl.pdf
12. Julious S.A. (2004). Sample sizes for clinical trials with normal data. Statistics in Medicine 23, 1921-1986.
13. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. & Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
14. Snapinn S.M. (2000). Noninferiority trials. Current Controlled Trials in Cardiovascular Medicine 1, 19-21.